HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels

Atherosclerosis

Volumn 159, Issue 1, 2001, Pages 27-33

  Martínez González, José ^a   Alfón, José ^a   Berrozpe, María ^a   Badimon, Lina ^a,b  

^a INST D INVESTIGACIONS B   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

HMG CoA reductase inhibitors; MCP 1; NOS II; Porcine model; Vessel wall

Indexed keywords

ATORVASTATIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE SYNTHASE; PRAVASTATIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; DRUG EFFECT; FEMORAL ARTERY; HYDROPHILICITY; HYPERCHOLESTEROLEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SWINE; THORACIC AORTA;

ANIMALS; AORTA; ARTERIES; ARTERIOSCLEROSIS; CAROTID ARTERIES; CHEMOKINE CCL2; CHOLESTEROL; CORONARY VESSELS; DOWN-REGULATION; FEMORAL ARTERY; GENE EXPRESSION; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; ILIAC ARTERY; IMMUNOHISTOCHEMISTRY; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PRAVASTATIN; PYRROLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SWINE;

EID: 0034747925     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(01)00469-5     Document Type: Article

References (44)

1. Studies on the pathogenesis of atherosclerosis I. Adhesion and migration of mononuclear cells in the aorta of hypercholesterolemic rats
2. Studies of hypercholesterolemia in the nonhuman primate Y. Changes that lead to fatty streak formation
3. Expression of monocyte chemoattractant protein 1 in macrophage rich areas of human and rabbit atherosclerotic lesions
4. Monocyte chemoattractant protein-1 in human atheromatous plaques
5. Detection of monocyte chemoattractant protein-1 in human atherosclerotic lesions by an anti-monocyte chemoattractant protein-1 monoclonal antibody
6. Monocyte chemotactic protein-1 gene and protein expression in atherogenesis of hypercholesterolemic rabbits
7. Elevated expression of monocyte chemoattractant protein 1 by vascular smooth muscle cells in hypercholesterolemic primates
8. Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1/JE
9. Expression of monocyte chemotactic protein and interleukin-8 by cytokine-activated human vascular smooth muscle cells
10. Minimally modified LDL induces monocyte chomotactic protein 1 in human endothelial and smooth muscle cells
11. Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor
12. Mice lacking the cc-chemokine MCP-1 are less susceptible to atherosclerosis
13. Statins do more than just lower cholesterol
14. Relationship between mevalonate pathway and arterial myocyte proliferation: In vitro studies with inhibitors of HMG-CoA reductase
15. Human and porcine smooth muscle cells share similar proliferation dependence on the mevalonate pathway: Implications for in vivo interventions in the porcine model
16. Esterified cholesterol accumulation induced by aggregated LDL uptake in human smooth muscle is reduced by HMG-CoA reductase inhibitors
17. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors
18. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages
19. Low-density lipprotein-independent effets of statins
20. Simvastatin, an HMG-Coenzyme A reductase inhibitor, improves endothelial function within 1 month
21. Effects of statins in thrombosis and aortic lesion development in a dyslipemic rabbit model
22. Pravastatin: An antithrombotic effect independent of the cholesterol-lowering effect
23. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells
24. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis
25. NOS II gene expression correlates with atherosclerotic intimal thickening. Preventive effect of HMG-CoA reductase inhibitors
26. Cloning and characterization of inducible nitric oxide synthase from mouse macrophages
27. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells
28. Superoxide and peroxynitrite in atherosclerosis
29. Nitric oxide and hypercholesterolemia: A matter of oxidation ans reduction?
30. Effects of reducing LDL and increasing HDL with gemfibrozil in experimental coronary lesion development and thrombotic risk
31. Manual of laboratory operation
32. Platelet deposition on eroded vessel wall at stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin
33. Improved nonradioactive RT-PCR method for relative quantification of mRNA
34. Swine as animal models in cardiovascular research
35. An HMG-CoA reductase inhibitor (cerivastatin) suppresses accumulation of macrophages expressing matrix metalloproteinases and tissue factor in atheroma of WHHL rabbits
36. Pravastatin attenuates cardiovascular inflammatory and proliferative changes in a rat model of chronic inhibition of nitric oxide synthesis by its cholesterol-lowering independent actions
37. Adenovirus-mediated overexpression of c-Jun and c-Fos induces intercellular adhesion molecule-1 and monocyte chemoattractant protein-1 in human endothelial cells
38. The nuclear factor-κB/inhibitor of kappa B autoregulatory sustem and atherosclerosis
39. Ras-dependent activation of MAP kinase pathway mediated by G-protein subunits
40. Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation
41. Mevalonate deprivation impairs IGF-I/insulin signaling in human vascular smooth muscle cells
42. Monocyte chemoattractant protein-1 is upregulated in rats with volume-overload congestive heart failure
43. Direct vascular effects of HMG-CoA reductase inhibitors
44. Low-density lipoprotein-independent effects of statins